Chiron Vaccines Get Shot In The Arm With PowderJect Needleless Technology
Executive Summary
Chiron will gain access to PowderJect's needleless vaccine technology and a platform through which to launch vaccines in the U.S. with its $878 mil. acquisition of the Fluvirin manufacturer